No difference in cerebral perfusion between the wild-type and the 5XFAD mouse model of Alzheimer's disease.

Neuroimaging with [2,2-dimethyl-3-[(2R,3E)-3-oxidoiminobutan-2-yl]azanidylpropyl]-[(2R,3E)-3-hydroxyiminobutan-2-yl]azanide;oxo(Tc)technetium-99(3+) ([Tc]HMPAO) single photon emission computed tomography (SPECT) is used in Alzheimer's disease (AD) to evaluate regional cerebral blood flow (rCBF). Hypoperfusion in select temporoparietal regions has been observed in human AD. However, it is unknown whether AD hypoperfusion signatures are also present in the 5XFAD mouse model.

Positron Emission Tomography/Computerized Tomography in Newly Diagnosed Patients with Giant Cell Arteritis Who Are Taking Glucocorticoids.

Objective: Large vessel uptake on positron emission tomography/computerized tomography (PET/CT) supports the diagnosis of giant cell arteritis (GCA). Its value, however, in patients without arteritis on temporal artery biopsy and in those receiving glucocorticoids remains unknown. We compared PET/CT results in GCA patients with positive (TAB+) and negative temporal artery biopsies (TAB-), and controls.

Spectrum of CT Findings in Thoracic Extranodal Non-Hodgkin Lymphoma.

Non-Hodgkin lymphoma (NHL) frequently manifests in extranodal structures in the chest, often in the form of secondary involvement but occasionally as primary disease. Because staging and treatment are affected by the presence of extranodal disease at imaging, radiologists' interpretation and management of suspicious findings are critical to patient care. Unfortunately, owing to considerable imaging overlap with other diseases, primary extranodal lymphoma is difficult to diagnose with imaging alone.

Myelofibrosis on F-18 FDG PET Imaging.

A 60-year-old male was referred for a positron emission tomography (PET) scan using F-18 fluoro-2-deoxyglucose (F-18 FDG) for evaluation of a right lung opacity identified on a computed tomography (CT) scan. The patient also had a history of idiopathic myelofibrosis. The PET scan revealed markedly increased uptake throughout the spleen and liver, which were massively enlarged.

Utility of 18F-FDG PET in evaluating cancers of lung.

PET has seen rapid progression in recent years, with applications in oncology leading the way. The glucose analog (18)F-FDG is the most commonly used PET radiopharmaceutical and has been shown to accumulate avidly in several different neoplasms, including cancers of the lung. The following discussion will review the physiologic basis for the uptake of (18)F-FDG in lung neoplasms and demonstrate the utility of (18)F-FDG PET in lung cancer.

2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants.

In the evaluation of tumors of the head and neck region, positron emission tomography (PET) using 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) is increasingly playing a valuable clinical role. However, assessment of this region can be challenging because of the large number of structures in this area which may demonstrate physiologically increased uptake of FDG. Furthermore, these structures are generally small, and uptake patterns can be quite variable, rendering the head and neck region one of the most difficult areas of the body to assess with FDG-PET.

Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.

Background: Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with (18)F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT).

Methods: Forty patients with advanced SCCHN were treated with ICT followed by CRT.